SY-1425

DRUG3 trials

Sponsors

Syros Pharmaceuticals Inc.

Conditions

Acute Myeloid Leukemia (AML) Myelodysplastic Syndrome (MDS)Newly Diagnosed RARA-positive Adult Patients with Higher-risk Myelodysplastic SyndromeRARA-positive acute myeloid leukemia

Phase 2

Tamibarotene in Combination with Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-positive AML Who are Ineligible for Standard Induction Therapy

CompletedCTIS2024-510939-21-00

Syros Pharmaceuticals Inc.RARA-positive acute myeloid leukemia

Start: 2022-04-01End: 2024-11-12Target: 60Updated: 2024-08-30

A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

CompletedCTIS2024-516281-11-00

Syros Pharmaceuticals Inc.Acute Myeloid Leukemia (AML) Myelodysplastic Syndrome (MDS)

Start: 2018-06-06End: 2024-11-21Target: 1Updated: 2024-09-05

Phase 3

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome

CompletedCTIS2023-510361-97-00

Syros Pharmaceuticals Inc.Newly Diagnosed RARA-positive Adult Patients with Higher-risk Myelodysplastic Syndrome

End: 2024-11-12Target: 417Updated: 2024-11-27